Company Overview of Jaguar Health, Inc.
Jaguar Health, Inc., a commercial stage natural-products pharmaceuticals company, focuses on developing novel, sustainably derived gastrointestinal products for human prescription use and animals worldwide. The company, through its wholly-owned subsidiary, Napo Pharmaceuticals, Inc., focuses on developing and commercializing proprietary human gastrointestinal pharmaceuticals for the global marketplace from plants used traditionally in rainforest areas. Its Mytesi (crofelemer) product is approved by the U.S. FDA for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. Canalevia is the company's lead animal prescription drug product candidate inte...
201 Mission Street
San Francisco, CA 94105
Key Executives for Jaguar Health, Inc.
CEO, President & Director
Total Annual Compensation: $446.2K
CFO & Treasurer
Total Annual Compensation: $243.4K
Executive VP of Sustainable Supply, Ethnobotanical Research & Intellectual Property and Secretary
Total Annual Compensation: $284.5K
Compensation as of Fiscal Year 2016.
Jaguar Health, Inc. Key Developments
Jaguar Health, Inc. Announces Changes
Apr 2 18
Jaguar Health, Inc. announced that on March 29, 2018, Dr. Ari Azhir notified the Board of Directors of the company of her intention to resign as a member of the Board, effective upon the close of business on March 29, 2018, including from her role as a member of the Audit Committee and Compensation Committee. Dr. Azhir is resigning to focus on other opportunities and her decision did not involve any disagreement with the company, its management or the Board. Dr. Azhir served as a director of the company since 2016. On March 29, 2018, the Board, by resolution as contemplated in the company's bylaws, appointed Mr. Jonathan B. Siegel, age 44, to fill the vacancy created by Dr. Azhir's resignation and serve as Class I director of the company until the 2019 annual meeting of stockholders or until his successor is elected and qualified. Mr. Siegel is founder of JBS Healthcare Ventures.
Jaguar Health, Inc. announced delayed annual 10-K filing
Apr 2 18
On 04/02/2018, Jaguar Health, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
Jaguar Health, Inc. Appoints Jeffrey C. Johnson as Class III Director and Member of the Compensation Committee
Mar 27 18
On March 19, 2018, the board of directors of Jaguar Health, Inc., by resolution as contemplated in the company's bylaws, increased the size of the board from seven to nine directors. In connection therewith, and to fill one of the two newly created vacancies, the board appointed Jeffrey C. Johnson to serve as a Class III director of the company until the 2018 annual meeting of stockholders or until his successor is elected and qualified, which appointment became effective as of the consummation of the Preferred Stock Offering. Mr. Johnson was also appointed by the board to serve as a member of its Compensation Committee. Mr. Johnson is a partner at Sagard Holdings, ULC and an investment manager at SCPM. He previously served as portfolio manager and senior analyst at Evercore Asset Management. He also serves on the board of directors of Peak Achievement Athletics and previously served on the board of directors of Vein Clinics of America.
Similar Private Companies By Industry
Recent Private Companies Transactions
March 26, 2018
March 23, 2018
March 21, 2018